← ANALYST RATINGS · TIPRANKS
ADC Therapeutics (ADCT): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy1 Hold0 Sell
Ratings of 2 analysts in the last 3 months12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $3.50, the highest $5.00, the lowest $2.00. The average is +150.0% from the last price of $1.40.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 | Hold | +42.9% | Upgrade | 14.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 | Sell | +42.9% | Downgrade | 14.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.50 → $2.00+33.3% | Hold | +42.9% | Reiterated | 13.10.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 → $2.00+33.3% | Hold | +42.9% | Reiterated | 13.10.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.50 → $2.00+33.3% | Hold | +42.9% | Reiterated | 13.10.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.50 → $2.00+33.3% | Hold | +42.9% | Reiterated | 13.10.26on TipRanks 01:05 | — | |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $2.00 | Hold | +42.9% | Reiterated | 08.10.26on TipRanks 21:45 | +8.2%next day +7.6% · 5 days −17.1% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $10.00 → $5.00−50.0% | Buy | +257.1% | Assigned | 14.08.26on TipRanks Aug 17 07:07 | −3.6%next day +9.4% · 5 days 0.0% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | — | Hold | — | Downgrade | 08.06.26on TipRanks 06:15 | −5.4%next day +12.9% · 5 days +5.4% | ↗ |
| Sudan Loganathan★★★★★★★★★★#1955 · hits 65% · avg +22.0% | Stephens | $5.00 | Buy | +257.1% | Assigned | 04.06.26on TipRanks 09:30 | −57.5%next day −19.4% · 5 days −17.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering ADC Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $3.50 at a price of $1.22 (+186.9%); now: $3.50 at $1.40 (+150.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 7 | 4 | 1 | 1 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 3 | 4 | 5 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.21 (from $-0.27 to $-0.19). Last quarter: $-0.11.
Sales
Next quarter’s sales estimate — $19M (from $17M to $22M). Last quarter: $19M.
Best top-analyst consensus in the sector · Healthcare
About ADC Therapeutics
- CEO: Ameet Mallik
- Employees: 191
- Biopole, Epalinges, VD, 1066, CH
- www.adctherapeutics.com
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Data from the stock’s TipRanks forecast page, read 43 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗